Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Melanoma

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 14 articles:
HTML format



Single Articles


    September 2025
  1. PASCH M, Tutein Nolthenius J
    Hutchinson's Sign in Subungual Melanoma In Situ.
    N Engl J Med. 2025;393:e13.
    PubMed    


    March 2025
  2. WOLCHOK JD, Hodi FS, Larkin J
    Nivolumab plus Ipilimumab in Advanced Melanoma. Reply.
    N Engl J Med. 2025;392:1246.
    PubMed    


  3. SANTHOSH A
    Nivolumab plus Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2025;392:1245-1246.
    PubMed    


    January 2025
  4. CURTI BD
    Checkpoint Immunotherapy for Melanoma - Offering Hope for Cure.
    N Engl J Med. 2025;392:81-82.
    PubMed    


    September 2024
  5. RUBIN EJ, Yeku OO, Morrissey S
    NEJM at ESMO - Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMe2411489.
    PubMed    


  6. WOLCHOK JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, et al
    Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2024 Sep 15. doi: 10.1056/NEJMoa2407417.
    PubMed     Abstract available


    June 2024
  7. LONG GV, Hauschild A, Santinami M, Kirkwood JM, et al
    Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
    N Engl J Med. 2024 Jun 19. doi: 10.1056/NEJMoa2404139.
    PubMed     Abstract available


  8. BLANK CU, Lucas MW, Scolyer RA, van de Wiel BA, et al
    Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
    N Engl J Med. 2024 Jun 2. doi: 10.1056/NEJMoa2402604.
    PubMed     Abstract available


    January 2024
  9. MOHAREB AM, Kang J, Montazeri K, Shroff SG, et al
    Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever.
    N Engl J Med. 2024;390:255-265.
    PubMed    


    October 2023
  10. HASSEL JC, Piperno-Neumann S, Rutkowski P, Baurain JF, et al
    Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
    N Engl J Med. 2023 Oct 21. doi: 10.1056/NEJMoa2304753.
    PubMed     Abstract available


    May 2023
  11. WEN L, Cai L
    Primary Diffuse Meningeal Melanomatosis.
    N Engl J Med. 2023;388:1892.
    PubMed    


    March 2023
  12. ROHAAN MW, Kessels R, Haanen JBAG
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma. Reply.
    N Engl J Med. 2023;388:859-860.
    PubMed    


  13. LIM AR, Shin SW
    Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma.
    N Engl J Med. 2023;388:859.
    PubMed    


  14. PATEL SP, Othus M, Chen Y, Wright GP Jr, et al
    Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
    N Engl J Med. 2023;388:813-823.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.